# Fulvestrant

## Faslodex inj 250mg-5mL

*藥物代碼*：IFAS

*給藥途徑*：I

*用法用量*：

Breast cancer, metastatic (postmenopausal women; HR positive): IM: Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once monthly. 
Breast cancer, advanced or metastatic (second-line endocrine-based combination therapy): Adult females (HR positive, HER-2 negative): IM: Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once every 28 days. Administer in combination with palbociclib (and an LHRH agonist [eg, goserelin] if pre- or perimenopausal); continue until disease progression or unacceptable toxicity. Note: Refer to Palbociclib monograph for dosing in combination with fulvestrant.

## Faslodex inj 250mg-5mL (sample)

*藥物代碼*：IFAS0

*給藥途徑*：I

*用法用量*：

Breast cancer, metastatic (postmenopausal women; HR positive): IM: Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once monthly. 
Breast cancer, advanced or metastatic (second-line endocrine-based combination therapy): Adult females (HR positive, HER-2 negative): IM: Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once every 28 days. Administer in combination with palbociclib (and an LHRH agonist [eg, goserelin] if pre- or perimenopausal); continue until disease progression or unacceptable toxicity. Note: Refer to Palbociclib monograph for dosing in combination with fulvestrant.

